- Home
- VTMX vs KNSA Comparison
VTMX vs KNSA Comparison
Compare VTMX & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTMX
- KNSA
- Stock Information
- Founded
- VTMX 1998
- KNSA 2015
- Country
- VTMX Mexico
- KNSA United Kingdom
- Employees
- VTMX N/A
- KNSA N/A
- Industry
- VTMX
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- VTMX
- KNSA Health Care
- Exchange
- VTMX Nasdaq
- KNSA Nasdaq
- Market Cap
- VTMX 2.3B
- KNSA 1.9B
- IPO Year
- VTMX 2023
- KNSA 2018
- Fundamental
- Price
- VTMX $27.08
- KNSA $28.23
- Analyst Decision
- VTMX Sell
- KNSA Strong Buy
- Analyst Count
- VTMX 2
- KNSA 5
- Target Price
- VTMX $27.50
- KNSA $38.80
- AVG Volume (30 Days)
- VTMX 184.5K
- KNSA 713.9K
- Earning Date
- VTMX 07-24-2025
- KNSA 07-22-2025
- Dividend Yield
- VTMX 2.58%
- KNSA N/A
- EPS Growth
- VTMX N/A
- KNSA N/A
- EPS
- VTMX 0.13
- KNSA N/A
- Revenue
- VTMX $258,927,122.00
- KNSA $481,166,000.00
- Revenue This Year
- VTMX $17.35
- KNSA $37.21
- Revenue Next Year
- VTMX $11.82
- KNSA $5.32
- P/E Ratio
- VTMX $20.52
- KNSA N/A
- Revenue Growth
- VTMX 15.06
- KNSA 59.45
- 52 Week Low
- VTMX $21.30
- KNSA $17.38
- 52 Week High
- VTMX $32.84
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- VTMX 37.76
- KNSA 51.94
- Support Level
- VTMX $27.03
- KNSA $27.62
- Resistance Level
- VTMX $27.82
- KNSA $28.69
- Average True Range (ATR)
- VTMX 0.47
- KNSA 1.11
- MACD
- VTMX -0.27
- KNSA -0.31
- Stochastic Oscillator
- VTMX 7.48
- KNSA 32.65
About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)
Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.